vomiting/neoplasms

BACKGROUND OF THE INVENTION 1. Field of Invention Cisplatin (cis-dichlorodiammine platinum II) is one of the more effective drugs used in cancer chemotherapy; however, the resulting violent emesis interferes with acceptance of therapy by the patient. This invention relates to an improvement in the

TECHNICAL FIELD The invention concerns a method for the management of cancer and treatment cancer comorbidities, including but not limited to cancer-related fatigue, cachexia, anorexia, pain, anemia, asthenia, depression, impaired cognitive function, loss of appetite, muscle weakness, nausea,

TECHNICAL FIELD The present invention relates to NK.sub.1 receptor antagonist useful as medicaments. More particularly, the present invention relates to NK.sub.1 receptor antagonist or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention generally relates to non-effervescent, solid dosage forms adapted for oral administration of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carb- azol-4-one (ondansetron) as an anti-emetic active

TECHNICAL FIELD The present invention relates to cyclohexyl pyridine derivatives useful as medicaments. More particularly, the present invention relates to cyclohexyl pyridine derivatives or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist

TECHNICAL FIELD The present invention relates to cyclohexyl pyridine derivatives useful as medicaments. More particularly, the present invention relates to cyclohexyl pyridine derivatives or pharmaceutically acceptable salts thereof which have substance P/neurokinin 1 (NK.sub.1) receptor antagonist

SUMMARY OF THE INVENTION This invention relates to novel substituted benzamides of the formula ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and A are as defined below, which are useful in the treatment of emesis, particularly chemotherapy-induced emesis, such as cisplatin treatment

FIELD OF THE INVENTION This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists

FIELD OF THE INVENTION The invention relates to a new aprepritant compositions and crystalline compounds containing aprepitant. More particularly, the invention relates to solvated aprepitant L-proline solvate compositions, aprepitant L-proline solvate cocrystals, therapeutic uses of the aprepitant

FIELD OF THE INVENTION The invention relates to a new aprepitant composition and a crystalline compound containing aprepitant, more particularly, the invention relates to an aprepitant L-proline composition, an aprepitant L-proline cocrystal, therapeutic uses of the aprepitant L-proline or the

BACKGROUND Cannabinoid receptors, CB1 and CB2, are part of the endocannabinoid system (ECS), which consists of cannabinoid receptors, endogenous endocannabinoids anandamide (AEA) and 2-arachindonoylglycerol (2-AG) and the hydrolytic enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol

FIELD OF THE INVENTION This invention relates to methods for discovering agonists and antagonists of the interaction between UDP-sugars (e.g.,UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetyl glucosamine) and their cellular receptor, human KIAA0001 receptor. The invention also

The present invention relates to compounds of formula I ##STR00002## wherein Y is C--R.sup.1'; R.sup.1' is hydrogen or halogen; R.sup.1 is hydrogen or halogen; R.sup.2 is hydrogen, lower alkyl or phenyl; R.sup.4 is hydrogen or lower alkyl; or R.sup.2 and R.sup.4 may form together with the

The present invention relates to compounds of formula I ##STR00001## wherein R.sup.1 is lower alkyl; R.sup.2 is phenyl or pyridinyl, wherein the N atom in the pyridinyl group may be in different positions; n is 0, 1 or 2; V/U are independently from each other O or CH.sub.2, wherein V and U cannot be

The present invention relates to compounds of formula I ##STR00001## wherein Y is N or C--R.sup.1'; G is a 5 or 6-membered aromatic or heteroaromatic ring containing 0, 1, 2 or 3 heteroatoms, selected from the group consisting of phenyl, pyridinyl with different N-positions, imidazolyl, pyrazinyl,